LT3065738T - Kompozicijos ir būdai, skirti x receptorių moduliavimui - Google Patents

Kompozicijos ir būdai, skirti x receptorių moduliavimui

Info

Publication number
LT3065738T
LT3065738T LTEP14803001.8T LT14803001T LT3065738T LT 3065738 T LT3065738 T LT 3065738T LT 14803001 T LT14803001 T LT 14803001T LT 3065738 T LT3065738 T LT 3065738T
Authority
LT
Lithuania
Prior art keywords
receptors
compositions
methods
modulating farnesoid
farnesoid
Prior art date
Application number
LTEP14803001.8T
Other languages
English (en)
Inventor
David Tully
Donatella Chianelli
Xiaodong Liu
Valentina Molteni
John Nelson
Jason ROLAND
Paul Rucker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51982773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3065738(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3065738T publication Critical patent/LT3065738T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
LTEP14803001.8T 2013-11-05 2014-11-04 Kompozicijos ir būdai, skirti x receptorių moduliavimui LT3065738T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900013P 2013-11-05 2013-11-05
PCT/US2014/063948 WO2015069666A1 (en) 2013-11-05 2014-11-04 Compositions and methods for modulating farnesoid x receptors

Publications (1)

Publication Number Publication Date
LT3065738T true LT3065738T (lt) 2018-05-10

Family

ID=51982773

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14803001.8T LT3065738T (lt) 2013-11-05 2014-11-04 Kompozicijos ir būdai, skirti x receptorių moduliavimui

Country Status (42)

Country Link
US (5) US9682939B2 (lt)
EP (1) EP3065738B1 (lt)
JP (1) JP6424231B2 (lt)
KR (1) KR102350357B1 (lt)
CN (1) CN105682656B (lt)
AP (1) AP2016009165A0 (lt)
AR (1) AR098316A1 (lt)
AU (1) AU2014346919B2 (lt)
BR (1) BR112016009630B1 (lt)
CA (1) CA2927705C (lt)
CL (1) CL2016000982A1 (lt)
CR (1) CR20160212A (lt)
CU (1) CU24375B1 (lt)
CY (1) CY1120273T1 (lt)
DK (1) DK3065738T3 (lt)
EA (1) EA030430B1 (lt)
ES (1) ES2670984T3 (lt)
GT (1) GT201600085A (lt)
HR (1) HRP20180817T1 (lt)
HU (1) HUE039155T2 (lt)
IL (1) IL245242B (lt)
JO (1) JO3454B1 (lt)
LT (1) LT3065738T (lt)
MA (1) MA39088B1 (lt)
MX (1) MX364834B (lt)
MY (1) MY175903A (lt)
NO (1) NO3105103T3 (lt)
NZ (1) NZ719078A (lt)
PE (1) PE20160682A1 (lt)
PH (1) PH12016500777B1 (lt)
PL (1) PL3065738T3 (lt)
PT (1) PT3065738T (lt)
RS (1) RS57179B1 (lt)
SG (1) SG11201603026PA (lt)
SI (1) SI3065738T1 (lt)
SV (1) SV2016005192A (lt)
TN (1) TN2016000143A1 (lt)
TR (1) TR201807321T4 (lt)
TW (1) TWI662027B (lt)
UY (1) UY35818A (lt)
WO (1) WO2015069666A1 (lt)
ZA (1) ZA201602555B (lt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
BR112016009630B1 (pt) 2013-11-05 2021-02-09 Novartis Ag receptores de farnesoide x, seus usos, combinação e composição farmacêutica
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CN107531721B (zh) * 2015-04-30 2020-07-17 诺华股份有限公司 用于调节法尼醇x受体的稠合的三环吡唑衍生物
MX384205B (es) 2016-02-22 2025-03-14 Novartis Ag Metodos para usar agonistas de fxr.
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
RU2019110779A (ru) * 2016-09-14 2020-10-15 Новартис Аг Новые схемы введения агонистов fxr
PE20190972A1 (es) * 2016-09-14 2019-07-09 Novartis Ag Combinacion de agonistas de fxr
RU2019113150A (ru) * 2016-10-05 2020-11-06 Новартис Аг Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
KR102643558B1 (ko) * 2017-06-05 2024-03-06 내셔널 유니버시티 오브 싱가포르 인간 트레포일 인자 3을 억제하는데 유용한 화합물
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
MA49903A (fr) * 2017-08-15 2020-06-24 Inflazome Ltd Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
US20200276178A1 (en) * 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
MA53388A (fr) 2018-07-25 2021-06-02 Novartis Ag Inhibiteurs d'inflammasome nlrp3
EP3911647B1 (en) 2019-01-15 2023-12-13 Gilead Sciences, Inc. Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
WO2021044351A1 (en) 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
CN113387828A (zh) * 2020-03-14 2021-09-14 江巨东 一种阿利克仑中间体的制备方法
WO2022037663A1 (zh) * 2020-08-21 2022-02-24 苏州晶云药物科技股份有限公司 苯甲酸衍生物的新晶型及其制备方法
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
IL319132A (en) * 2022-08-26 2025-04-01 Celmatix Inc New FSHR modulators and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
CN101448791B (zh) * 2006-05-24 2011-11-16 伊莱利利公司 Fxr激动剂
WO2008033534A2 (en) * 2006-09-15 2008-03-20 Thales Avionics, Inc. System and method for wirelessly transferring content to and from an aircraft
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
BR112016009630B1 (pt) 2013-11-05 2021-02-09 Novartis Ag receptores de farnesoide x, seus usos, combinação e composição farmacêutica
CN107531721B (zh) 2015-04-30 2020-07-17 诺华股份有限公司 用于调节法尼醇x受体的稠合的三环吡唑衍生物

Also Published As

Publication number Publication date
IL245242A0 (en) 2016-06-30
IL245242B (en) 2019-03-31
US20190062283A1 (en) 2019-02-28
EP3065738A1 (en) 2016-09-14
US20160340317A1 (en) 2016-11-24
NZ719078A (en) 2018-07-27
US10683271B2 (en) 2020-06-16
EA030430B1 (ru) 2018-08-31
UY35818A (es) 2015-05-29
CL2016000982A1 (es) 2016-10-07
EA201690930A1 (ru) 2016-08-31
AU2014346919A1 (en) 2016-05-12
TR201807321T4 (tr) 2018-06-21
CN105682656B (zh) 2019-11-05
CA2927705C (en) 2021-09-21
KR20160079091A (ko) 2016-07-05
CY1120273T1 (el) 2019-07-10
PL3065738T3 (pl) 2018-07-31
US10077240B2 (en) 2018-09-18
GT201600085A (es) 2019-07-19
MY175903A (en) 2020-07-15
SI3065738T1 (en) 2018-06-29
TN2016000143A1 (en) 2017-10-06
PT3065738T (pt) 2018-06-04
PH12016500777A1 (en) 2016-05-30
RS57179B1 (sr) 2018-07-31
MX364834B (es) 2019-05-08
SG11201603026PA (en) 2016-05-30
US20200247757A1 (en) 2020-08-06
NO3105103T3 (lt) 2018-05-12
TW201612163A (en) 2016-04-01
TWI662027B (zh) 2019-06-11
MA39088A1 (fr) 2017-07-31
SV2016005192A (es) 2016-11-21
JP6424231B2 (ja) 2018-11-14
MX2016005865A (es) 2016-07-13
US11021446B2 (en) 2021-06-01
PE20160682A1 (es) 2016-07-23
DK3065738T3 (en) 2018-06-06
WO2015069666A1 (en) 2015-05-14
HUE039155T2 (hu) 2018-12-28
HRP20180817T1 (hr) 2018-06-29
CA2927705A1 (en) 2015-05-14
US20170275256A1 (en) 2017-09-28
CN105682656A (zh) 2016-06-15
ZA201602555B (en) 2017-06-28
AU2014346919B2 (en) 2017-02-02
JP2016535784A (ja) 2016-11-17
US9682939B2 (en) 2017-06-20
CU24375B1 (es) 2018-12-05
KR102350357B1 (ko) 2022-01-14
CR20160212A (es) 2016-07-22
AP2016009165A0 (en) 2016-04-30
MA39088B1 (fr) 2018-06-29
AR098316A1 (es) 2016-05-26
JO3454B1 (ar) 2020-07-05
BR112016009630A8 (pt) 2020-04-07
ES2670984T3 (es) 2018-06-04
BR112016009630B1 (pt) 2021-02-09
PH12016500777B1 (en) 2016-05-30
US20210253534A1 (en) 2021-08-19
CU20160063A7 (es) 2016-09-30
EP3065738B1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
IL245242B (en) Preparations and methods for modulation of paranoid x receptors
IL274064B (en) Compositions and methods for modulating apolipoprotein expression
IL260378B (en) Preparations for the modulation of tau expression
IL244759A0 (en) Preparations for modulation of c9orf72 expression
IL245550A0 (en) Preparations and methods for using transposons
IL244081A0 (en) Preparations and methods for modulating RNA
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
GB2520795B (en) Compositions and methods
IL241439A0 (en) Preparations and methods for modulation of tau expression
ZA201506874B (en) Binder compositions and methods for making and using same
AP2014008100A0 (en) Compositions and methods for modulating hemoglobingene family expression
GB201308072D0 (en) Compositions and methods
IL243553B (en) Preparations and methods for dental mineralization
EP2966975A4 (en) POLLINATION ENHANCEMENT COMPOSITIONS AND METHOD FOR THEIR USE
GB201305813D0 (en) Compositions and methods
ZA201506873B (en) Binder compositions and methods for making and using same
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods